ProfileGDS5678 / 1441026_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 57% 51% 52% 48% 49% 49% 50% 56% 57% 51% 51% 44% 58% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2565850
GSM967853U87-EV human glioblastoma xenograft - Control 23.4678557
GSM967854U87-EV human glioblastoma xenograft - Control 33.2158151
GSM967855U87-EV human glioblastoma xenograft - Control 43.2078952
GSM967856U87-EV human glioblastoma xenograft - Control 53.0868848
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2773449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.2459749
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.1982650
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3816356
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4195257
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.222351
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1832551
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0287744
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.497158